Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 67.40
Bid: 66.40
Ask: 69.80
Change: 3.00 (4.66%)
Spread: 3.40 (5.12%)
Open: 63.00
High: 69.00
Low: 63.00
Prev. Close: 64.40
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Liquidity Agreement and Total Voting Rights

1 Jul 2021 14:30

RNS Number : 8895D
Novacyt S.A.
01 July 2021
 

Novacyt S.A.

 

("Novacyt" or the "Company")

 

Liquidity Agreement Monthly Update and

Total Voting Rights

 

Paris, France and Camberley, UK - 1 July 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the "Liquidity Agreement"). The Liquidity Agreement is governed by French law and is further summarised in the 'notes for editors' section below.

 

During the period from 1 June to 30 June 2021, Invest Securities purchased 3,772 ordinary shares at a maximum price of €4.35 and a minimum price of €3.72 and sold 3,996 ordinary shares at a maximum price of €4.65 and a minimum price of €3.79 under the Liquidity Agreement. The total number of ordinary shares in the Company, which are held in treasury as at close of business on 30 June 2021, is 12,543.

 

Total Voting Rights

 

The total number of ordinary shares in the Company is 70,626,248. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company's Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial Conduct Authority under Part VI of FSMA.

 

For further information, please refer to www.novacyt.com or contact:

 

Novacyt SA

Graham Mullis, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com/ y.petit@allegrafinance.com 

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / Alex.Shaw@fticonsulting.com 

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com 

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information please refer to the website: www.novacyt.com

 

Further information on the Liquidity Agreement

On 12 September 2016, the Company and Invest Securities entered into the Liquidity Agreement pursuant to which Invest Securities provides liquidity services in relation to the ordinary shares to the Company. Invest Securities may purchase ordinary shares on behalf of the Company under the agreement, subject to approval from Shareholders as to the price at which ordinary shares can be brought back and the aggregate amount that the Company may provide to Invest Securities to purchase such ordinary shares.

 

Shareholder approval was granted at the Shareholders' meeting held on 29 September 2020 for the purchase of ordinary shares by Invest Securities under the agreement at a maximum purchase price per ordinary shares of €12.00 for an aggregate maximum purchase price of €200,000 and for 18 months from the date of the approval. Under the agreement, Invest Securities must act completely independently of the Company and the Company must not communicate with the employees of Invest Securities who are responsible for performing the agreement. Invest Securities is paid €10,000 per annum for its services under the liquidity agreement. The agreement has an initial term of two years, with a rolling extension of one year thereafter. The agreement can be terminated by either party at the end of each such period subject to two months' prior notice. The Liquidity Agreement is governed by French law. Ordinary shares purchased by Invest Securities are either cancelled or held as treasury shares (which are non-voting and do not rank for dividends).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRLFLFBFDLZBBK
Date   Source Headline
19th Apr 20247:00 amRNSDHSC Claim update – Pre-Trial Review
11th Apr 20247:00 amRNSDirectorate Changes and FY 23 results update
2nd Apr 20244:00 pmRNSLiquidity Agreement and Total Voting Rights
1st Mar 202412:30 pmRNSLiquidity Agreement and Total Voting Rights
6th Feb 20247:00 amRNSUpdate on Taiwanese divestment
1st Feb 20241:00 pmRNSLiquidity Agreement and Total Voting Rights
25th Jan 20247:00 amRNSTrading update
3rd Jan 202411:00 amRNSLiquidity Agreement and Total Voting Rights
2nd Jan 20247:00 amRNSAppointment of CFO
21st Dec 20237:00 amRNSUpdate on Taiwan laboratory disposal
1st Dec 202311:45 amRNSLiquidity Agreement and Total Voting Rights
7th Nov 20237:00 amRNSIVDR certification for DPYD genotyping assay
1st Nov 20232:30 pmRNSLiquidity Agreement and Total Voting Rights
26th Oct 20233:20 pmRNSResult of AGM
11th Oct 20237:00 amRNSAGM voting
5th Oct 20232:15 pmRNSNotice of rescheduled AGM
2nd Oct 20231:30 pmRNSLiquidity Agreement and Total Voting Rights
28th Sep 20233:15 pmRNSReminder to shareholders re. AGM voting
28th Sep 20237:00 amRNS2023 Interim Results
14th Sep 20237:00 amRNSAGM voting
13th Sep 20237:00 amRNSNotice of Results
11th Sep 20237:55 amRNSCancellation of trading of Yourgene Shares
8th Sep 202312:00 pmRNSCompletion of acquisition of Yourgene Health plc
8th Sep 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
7th Sep 202312:22 pmRNSCourt sanction of the Scheme of Arrangement
1st Sep 202312:30 pmRNSLiquidity Agreement and Total Voting Rights
29th Aug 20237:00 amRNSNotice of rescheduled AGM
17th Aug 20235:16 pmRNSAcquisition update
1st Aug 202311:45 amRNSLiquidity Agreement and Total Voting Rights
27th Jul 20237:00 amRNSHalf Year Trading Update
19th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
18th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
17th Jul 202312:00 pmRNSForm 8.5 (EPT/RI)
14th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
13th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
13th Jul 20237:00 amRNSNotice of cancelled AGM
12th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
11th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
10th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
7th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
6th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
5th Jul 20231:27 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc Amended
5th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
4th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
3rd Jul 202312:00 pmRNSLiquidity Agreement and Total Voting Rights
3rd Jul 20237:01 amRNSRecommended cash offer for Yourgene Health plc
15th Jun 20234:00 pmRNSNotice of rescheduled AGM
12th Jun 20237:00 amRNSReminder to shareholders re. AGM voting
1st Jun 20231:00 pmRNSLiquidity Agreement and Total Voting Rights
26th May 20237:00 amRNSPublication of Annual Report and AGM voting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.